$16.51
1.6010.73%
At close: -
$16.51
0.000.00%
After Hours: Apr 11, 4:00 PM EDT
Comments
Loading...
Enliven Therapeutics Analyst Ratings and Price Targets | NASDAQ:ELVN | Benzinga
Enliven Therapeutics Inc has a consensus price target of $36.33 based on the ratings of 7 analysts. The high is $42 issued by BTIG on December 13, 2024. The low is $27 issued by Jefferies on March 29, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., BTIG, and Baird on March 21, 2025, December 13, 2024, and November 15, 2024, respectively. With an average price target of $40.33 between HC Wainwright & Co., BTIG, and Baird, there's an implied 144.30% upside for Enliven Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BTIG
Baird
Jones Trading
Mizuho
1calculated from analyst ratings
Analyst Ratings for Enliven Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/21/2025 | Buy Now | 136.22% | HC Wainwright & Co. | Robert Burns39% | $37 → $39 | Maintains | Buy | Get Alert |
| 12/13/2024 | Buy Now | 154.39% | BTIG | Justin Zelin41% | → $42 | Initiates | → Buy | Get Alert |
| 11/15/2024 | Buy Now | 142.28% | Baird | Colleen Kusy33% | $32 → $40 | Maintains | Outperform | Get Alert |
| 10/31/2024 | Buy Now | 118.05% | Jones Trading | Soumit Roy32% | → $36 | Initiates | → Buy | Get Alert |
| 10/01/2024 | Buy Now | 124.11% | HC Wainwright & Co. | Robert Burns39% | $37 → $37 | Reiterates | Buy → Buy | Get Alert |
| 09/09/2024 | Buy Now | 124.11% | HC Wainwright & Co. | Robert Burns39% | → $37 | Initiates | → Buy | Get Alert |
| 06/11/2024 | Buy Now | 93.82% | Baird | Colleen Kusy33% | → $32 | Initiates | → Outperform | Get Alert |
| 04/09/2024 | Buy Now | 105.94% | Mizuho | Salim Syed43% | → $34 | Initiates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 63.54% | Jefferies | Eun Yang34% | → $27 | Initiates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | — | TD Cowen | Phil Nadeau64% | — | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Enliven Therapeutics (ELVN) stock?
The latest price target for Enliven Therapeutics (NASDAQ:ELVN) was reported by HC Wainwright & Co. on March 21, 2025. The analyst firm set a price target for $39.00 expecting ELVN to rise to within 12 months (a possible 136.22% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enliven Therapeutics (ELVN)?
The latest analyst rating for Enliven Therapeutics (NASDAQ:ELVN) was provided by HC Wainwright & Co., and Enliven Therapeutics maintained their buy rating.
When was the last upgrade for Enliven Therapeutics (ELVN)?
There is no last upgrade for Enliven Therapeutics
When was the last downgrade for Enliven Therapeutics (ELVN)?
There is no last downgrade for Enliven Therapeutics.
When is the next analyst rating going to be posted or updated for Enliven Therapeutics (ELVN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enliven Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enliven Therapeutics was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.
Is the Analyst Rating Enliven Therapeutics (ELVN) correct?
While ratings are subjective and will change, the latest Enliven Therapeutics (ELVN) rating was a maintained with a price target of $37.00 to $39.00. The current price Enliven Therapeutics (ELVN) is trading at is $16.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.